New Flatiron–Guardant collaboration streamlines oncology clinician access to precision medicine tools at the point-of-care

Flatiron Health and Guardant Health announce integration of Guardant’s genomic profiling into Flatiron’s patient record management platform, streamlining oncology clinician access to precision medicine tools at the point-of-care by enabling order and receipt of test results directly within individuals’ electronic medical records.

Precision oncology company Guardant Health and Flatiron Health, a health tech company focused on point-of-care solutions in oncology, have announced a collaboration to integrate Guardant’s comprehensive genomic profiling tests within Flatiron’s cloud-based oncology electronic medical record (EMR) management platform OncoEMR^®. Seamless order and receipt of molecular profile test results directly within patient records gives oncologists convenient access to the information they need to practice precision medicine.

Oncology clinicians use molecular profiling to help select the best treatment for patients with advanced cancer and to monitor for recurrence in patients with early-stage cancer. Simplified access to this critical data that informs patient care decisions will be gained through the new Molecular Profiling Integration on the OncoEMR platform under the Flatiron–Guardant collaboration. Users will be able to submit Guardant Health test orders, track real-time status updates, and receive test results directly in individuals’ EMRs, streamlining physicians’ workflows and reducing ordering time.

“Genomic profiling provides critical data that helps oncologists make timely and informed decisions about personalized treatment plans for their patients,” said Chris Freeman, Guardant Health Chief Commercial Officer. “This integration with the OncoEMR platform, which reaches almost 40% of US community oncologists, will simplify access to our tests and enable a significant step forward in our mission to conquer cancer with data.”

Over 2000 clinicians within the Flatiron network, which includes more than 800 community-based cancer care locations across the US, will have access to Guardant Health’s entire portfolio of advanced blood and tissue tests for early- and advanced-stage cancer through the Molecular Profiling Integration. The companies beta-tested the integration at multiple oncology practice sites across the US earlier this year – seeing >75% utilization of the integration versus traditional ordering workflows – and plan to roll the integration out to the entire OncoEMR network over the next several months.

“By offering integrated test ordering and reporting for Guardant Health’s genomic profiling tests within OncoEMR, we are enabling oncologists with the tools they need to further expand possibilities at the point-of-care,” said James Hamrick, Vice President, Clinical Oncology at Flatiron Health. “The integration gives oncologists convenient access to the information they need to practice precision medicine, contributing to better patient outcomes, more time with patients, and a better care experience for physicians and their patients.”

Guardant Health tests are also available through other EMR/EHR systems that reach oncology practices in community and academic settings.